🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Torrent Pharmaceuticals Limited TORNTPHARM NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.torrentpharma.com
Company Profile ↓
₹4,952.20
+49.61% 1Y
Mkt Cap₹1.68 L Cr
P/E87.70
P/B19.98
Div. Yield0.78%
52W High₹4,952.20
52W Low₹3,285.10
Book Value₹247.85
EPS (TTM)₹56.47

Company Overview

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 25.8%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 20.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 13.3% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 15.7%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹13,752.99 Cr (+21.5% YoY); net profit ₹2,163.37 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +21.5%, earnings +13.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 13.3%, profit CAGR 20.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:13.27%
1 Year:21.52%

Compounded Profit Growth

5 Years:20.22%
1 Year:13.19%

Stock Price Performance

1 Year:+49.61%
6 Months:+26.06%
3 Months:+19.40%
1 Month:+9.95%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹3,285.10 ₹4,952.20
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)79.17 · Overbought
Price Performance
1M+9.95%
3M+19.40%
6M+26.06%
1Y+49.61%
Valuation vs Sector

P/E of 87.70 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 25.8%.
  • Compounding revenue at 13.3% over 5 years.
  • Profit CAGR of 20.2% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 87.7.
  • RSI at 79 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
87.70
Industry PE
39.97
Forward P/E
52.71
PEG Ratio
-
Book Value
₹247.85
Price to Book
19.98
P/S
11.99
EV/EBITDA
42.13
Dividend Yield
0.78%

Growth (CAGR)

Revenue 5Y
13.27%
Profit 5Y
20.22%
Revenue (YoY)
21.52%
Earnings (YoY)
13.19%

Profitability & Returns

ROCE
9.05%
ROE
25.79%
ROA
4.88%
Profit Margin
15.73%
Op Margin
25.01%
Gross Margin
74.37%
EPS (Latest Qtr)
₹11.51
EPS (TTM)
₹56.47

Balance Sheet & Liquidity

Debt/Equity
1.79
Quick Ratio
0.75
Current Ratio
1.13
Debt
₹15,025.50 Cr
Total Assets
₹44,311.96 Cr
Current Assets
₹9,391.89 Cr
Working Capital
₹1,048.56 Cr

Ownership

Promoter Holding
71.19%
Chg in Prom Hold
2.88%
FII / Inst Holding
15.82%
Chg in FII Hold
-0.06%

Financial Snapshot

Enterprise Value
₹1.68 L Cr
Total Revenue (TTM)
₹13,752.99 Cr
EBITDA
₹4,375.75 Cr
Free Cash Flow
₹2,345.32 Cr
Operating Cash Flow
₹3,022.71 Cr
Shares Outstanding
₹33.84 Cr
Gross Margin
74.37%
Payout Ratio
54.76%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
6 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
7 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
8 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,562.00 55.36 ₹1.06 L Cr 0.08% 13.75% 11.74% 17.73% 14.28%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 2,491.00 Cr2,591.00 Cr2,660.00 Cr2,732.00 Cr2,745.00 Cr2,859.00 Cr2,889.00 Cr2,809.00 Cr2,909.00 Cr3,128.00 Cr3,246.00 Cr3,251.00 Cr4,128.00 Cr
Cost of Revenue --------731.00 Cr774.00 Cr800.00 Cr799.00 Cr1,015.00 Cr
Gross Profit --------2,178.00 Cr2,354.00 Cr2,446.00 Cr2,452.00 Cr3,113.00 Cr
Operating Expenses 1,764.00 Cr1,800.00 Cr1,835.00 Cr1,863.00 Cr1,862.00 Cr1,955.00 Cr1,950.00 Cr1,895.00 Cr1,415.00 Cr1,523.00 Cr1,567.00 Cr1,570.00 Cr2,265.00 Cr
Operating Income 531.00 Cr600.00 Cr624.00 Cr656.00 Cr680.00 Cr707.00 Cr741.00 Cr715.00 Cr763.00 Cr831.00 Cr879.00 Cr882.00 Cr848.00 Cr
EBITDA 727.00 Cr791.00 Cr825.00 Cr869.00 Cr883.00 Cr904.00 Cr939.00 Cr914.00 Cr922.00 Cr995.00 Cr1,043.00 Cr1,065.00 Cr1,273.00 Cr
Interest Expense 107.00 Cr103.00 Cr91.00 Cr80.00 Cr80.00 Cr75.00 Cr64.00 Cr57.00 Cr56.00 Cr56.00 Cr48.00 Cr45.00 Cr236.00 Cr
Pretax Income 433.00 Cr531.00 Cr559.00 Cr631.00 Cr631.00 Cr656.00 Cr661.00 Cr691.00 Cr665.00 Cr738.00 Cr791.00 Cr814.00 Cr529.00 Cr
Tax Provision 147.22 Cr153.99 Cr173.29 Cr189.30 Cr182.99 Cr196.80 Cr204.91 Cr186.57 Cr167.00 Cr190.00 Cr200.00 Cr179.00 Cr165.00 Cr
Net Income 287.00 Cr378.00 Cr386.00 Cr443.00 Cr449.00 Cr457.00 Cr453.00 Cr503.00 Cr498.00 Cr548.00 Cr591.00 Cr635.00 Cr389.00 Cr
Diluted EPS 8.4811.1711.4113.0913.2713.5013.3814.8614.7116.1917.4518.7711.51

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 4,636.00 Cr6,687.00 Cr5,816.00 Cr5,950.00 Cr7,673.00 Cr7,939.00 Cr8,005.00 Cr-9,463.69 Cr10,562.31 Cr11,317.25 Cr13,752.99 Cr
Cost of Revenue --------2,827.69 Cr2,787.73 Cr2,884.49 Cr3,525.11 Cr
Gross Profit --------6,636.00 Cr7,774.58 Cr8,432.76 Cr10,227.88 Cr
Operating Expenses 3,616.00 Cr3,954.00 Cr4,438.00 Cr4,601.00 Cr5,690.00 Cr5,769.00 Cr5,524.00 Cr-4,495.98 Cr5,202.23 Cr5,506.70 Cr6,788.12 Cr
Operating Income 829.00 Cr2,495.00 Cr1,070.00 Cr940.00 Cr1,365.00 Cr1,516.00 Cr1,822.00 Cr-2,140.02 Cr2,572.35 Cr2,926.06 Cr3,439.76 Cr
EBITDA 1,020.00 Cr2,733.00 Cr1,377.00 Cr1,349.00 Cr1,983.00 Cr2,170.00 Cr2,480.00 Cr-2,881.43 Cr3,500.04 Cr3,719.12 Cr4,375.75 Cr
Interest Expense 175.00 Cr184.00 Cr206.00 Cr308.00 Cr504.00 Cr451.00 Cr353.00 Cr-332.24 Cr352.63 Cr251.38 Cr384.69 Cr
Pretax Income 940.00 Cr2,343.00 Cr1,088.00 Cr931.00 Cr562.00 Cr1,187.00 Cr1,526.00 Cr-1,847.16 Cr2,352.11 Cr2,672.81 Cr2,872.19 Cr
Tax Provision 188.00 Cr609.18 Cr152.32 Cr251.37 Cr123.64 Cr166.18 Cr274.68 Cr-601.93 Cr695.73 Cr761.56 Cr734.01 Cr
Net Income 751.00 Cr1,733.00 Cr934.00 Cr678.00 Cr436.00 Cr1,025.00 Cr1,252.00 Cr-1,245.23 Cr1,656.38 Cr1,911.25 Cr2,163.37 Cr
Diluted EPS 22.1951.2227.5920.0412.8930.2836.9922.9636.7948.9456.47-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 7,820.00 Cr8,886.00 Cr9,601.00 Cr14,243.00 Cr14,113.00 Cr14,010.00 Cr14,075.00 Cr-15,011.85 Cr15,060.58 Cr14,989.74 Cr44,311.96 Cr
Current Assets --------5,313.72 Cr5,611.48 Cr5,622.57 Cr9,391.89 Cr
Cash & Equivalents --------508.53 Cr835.14 Cr573.48 Cr1,117.20 Cr
Inventory --------2,229.64 Cr2,279.07 Cr2,541.25 Cr3,138.19 Cr
Receivables --------1,943.82 Cr1,844.30 Cr1,866.45 Cr3,030.86 Cr
Total Liabilities --------8,813.78 Cr8,204.43 Cr7,399.05 Cr26,727.13 Cr
Current Liabilities --------5,447.30 Cr5,425.25 Cr4,717.19 Cr8,343.33 Cr
Long Term Debt --------2,496.22 Cr1,603.78 Cr1,191.75 Cr11,651.17 Cr
Total Debt 2,740.00 Cr2,352.00 Cr2,510.00 Cr6,462.00 Cr6,038.00 Cr5,784.00 Cr4,874.00 Cr-5,368.56 Cr4,021.94 Cr3,202.32 Cr15,025.50 Cr
Total Equity 2,491.00 Cr3,494.00 Cr4,351.00 Cr4,623.00 Cr4,725.00 Cr4,824.00 Cr5,838.00 Cr-6,198.07 Cr6,856.15 Cr7,590.69 Cr8,388.43 Cr
Shares Outstanding --------33.84 Cr33.84 Cr33.84 Cr33.84 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 810.00 Cr2,742.00 Cr1,009.00 Cr894.00 Cr1,798.00 Cr1,393.00 Cr2,005.00 Cr-2,368.13 Cr3,266.08 Cr2,585.11 Cr3,022.71 Cr
Investing Cash Flow -2,113.00 Cr-869.00 Cr-798.00 Cr-4,677.00 Cr-246.00 Cr229.00 Cr-444.00 Cr--2,415.31 Cr-167.90 Cr-540.05 Cr-12,712.41 Cr
Financing Cash Flow 1,212.00 Cr-1,435.00 Cr-193.00 Cr3,417.00 Cr-1,314.00 Cr-1,549.00 Cr-1,651.00 Cr-77.36 Cr-2,779.64 Cr-2,297.99 Cr10,150.60 Cr
Capital Expenditure -236.00 Cr-592.00 Cr-486.00 Cr-789.00 Cr-660.00 Cr-403.00 Cr-334.00 Cr--573.94 Cr-432.78 Cr-611.87 Cr-677.39 Cr
Free Cash Flow 574.00 Cr2,150.00 Cr523.00 Cr105.00 Cr1,138.00 Cr990.00 Cr1,671.00 Cr-1,794.19 Cr2,833.30 Cr1,973.24 Cr2,345.32 Cr
Net Change in Cash -90.00 Cr437.00 Cr18.00 Cr-366.00 Cr238.00 Cr73.00 Cr-89.00 Cr-30.18 Cr318.54 Cr-252.93 Cr460.90 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------70.1%73.6%74.5%74.4%
Operating Margin % 17.9%37.3%18.4%15.8%17.8%19.1%22.8%-22.6%24.4%25.9%25.0%
Net Margin % 16.2%25.9%16.1%11.4%5.7%12.9%15.6%-13.2%15.7%16.9%15.7%
ROE % 30.1%49.6%21.5%14.7%9.2%21.2%21.4%-20.1%24.2%25.2%25.8%
ROCE % --------22.4%26.7%28.5%9.6%

Shareholding Pattern

Insiders
71.19%
Institutions
15.82%
Public Float
54.92%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TORNTPHARM

Google News hu, 25 Jun 2026

TORNTPHARM Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE8xdkY4enZKNEdWaG0wR3RqWVNfVUhYaXdyUmxWMmE1RUktVENSZTVwa3A1OEJHRWtxYlZfNWVXbUdnbE5PUW81c3VfWUVZLWQ3SC12V09Ld3Zqai05ekJTYjdOZzlzMHV0dUZ5SGlRM0JNTWpTTllXZ1lvU0h3dw?oc=5" target="_blan…

Google News Fri, 10 Jul 2026

TORNTPHARM Share Price Today - Torrent Pharmaceuticals on NSE/BSE - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE90a0Mzdi1XV0kxWnBqQjlHV19VNURDSUNfQUxqbXM3V05qZEFzMXBJa0tIV2NnZzBCRGw2V2FmVkQyM0R3dzRKbVdldEFldDVUaGtxM3BrcE5IR3dNWnpZb0l1MGpRZw?oc=5" target="_blank">TORNTPHARM Share Price Today …

Google News Fri, 10 Jul 2026

TORNTPHARM Outlook for the Week (July 13, 2026 – July 17, 2026) - Equitypandit

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1HVVRmQmxvLW9wak5lZ08zZFNyYzYxOUhJNDJrQjJmaWRuT2pTMkVIZHhKdS14ZjhkOHBCN3c5Y1FOU3YxdnBvd3Q5MTlDX0t6NnpzTGx3NHl2d3pPSDNuZXVYYzUzRVdJMk9hcnBB?oc=5" target="_blank">TORNTPHARM Outlook …

Google News Wed, 27 May 2026

Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxNTGl2ZC04cHR5c1RQaVJkSG9fbXEyTUw1bXJOZUlVSlFqczZXNGdKWWdPbzdLeVhnYzZDVkNTV3Q3dmo4ZW10NE9pNkpFMDRGRUVNOXloRDVzbkR5SWxLb2Z3WUdCbHAyN1ZwSUFid2Vfbzg1cjg5aHMxT1YzQWthTjduSFJ0b2Y3X09tVF…

Google News ue, 23 Jun 2026

Torrent Pharmaceuticals Limited Approves Final Dividend for the Financial Year Ended 31 March, 2026 - marketscreener.com

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxPekRCNFltbmotNy1LZUtnYU9TdVJQTk5KMFNYLUEybnJpNmpUbVY1eUx0QzVDREV0S1AtR1I1Nkdta0JIN0hRTDIwck52QXhVekd4QlZQZjdUaUVRNDl1QWhtRXVDWnFjcUg1eEFCcXMzYUczem5nMFpBV1M1di1Dc1huaUVZMXpXNC1BcF…

Google News hu, 15 Jan 2026

Is Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Recent Stock Performance Tethered To Its Strong Fundamentals? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi_gFBVV95cUxNNVdITUI5MlhoSzc1Nnl6Q2UtUHdRLXkxcHpZbmlCdUNjczBMZlFqZXgxRXJLajdUdU4xNXJ6REhjR3RGVlpkVGxMUDdwdUd5WVhGUUFEb3NPQk04d1pmZy1xQjBMNmJOZGUxQnV1b3Ryc1NtVkdSVk5lVzQxQ2FreVZsS2ZPUGFzT003RW…

TORNTPHARM — Frequently Asked Questions

What is the current share price of Torrent Pharmaceuticals Limited (TORNTPHARM)?

As of 2026-07-15 09:52 IST, Torrent Pharmaceuticals Limited (TORNTPHARM) trades at ₹4,952.20 on NSE. Its 52-week range is ₹3,285.10 to ₹4,952.20.

What is the market capitalisation of TORNTPHARM?

Torrent Pharmaceuticals Limited (TORNTPHARM) has a market capitalisation of ₹1.68 L Cr on NSE.

What is the P/E ratio of TORNTPHARM?

TORNTPHARM trades at a trailing price-to-earnings (P/E) ratio of 87.70. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 19.98.

Does TORNTPHARM pay a dividend?

Torrent Pharmaceuticals Limited (TORNTPHARM) currently offers a dividend yield of 0.78%.

What is the return on equity (ROE) of TORNTPHARM?

TORNTPHARM has a return on equity (ROE) of 25.79%. Its return on capital employed (ROCE) is 9.05%.

Is TORNTPHARM a good stock to buy?

This page provides a data-driven analysis of Torrent Pharmaceuticals Limited (TORNTPHARM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space